For questions about BMS medicines during this time please call 1-800-721-8909.

This site is intended for U.S. audiences only.

ONUREG® is the first FDA-approved continued treatment for people with AML who are in first remission

ONUREG® is a prescription medicine used for continued treatment of adults with acute myeloid leukemia (AML) who:

  • had a first complete remission (CR) following intensive induction chemotherapy with or without
    recovery of your blood cell counts, and
  • who are not able to complete intensive curative therapy.

It is not known if ONUREG® is safe and effective in children under 18 years of age.

Helpful resources to download

ONUREG® Patient Information

ONUREG® Patient Brochure

Have Questions About Our Services or Possible Financial Support?

Call Bristol Myers Squibb Access Support® at
1-800-861-0048, 8 am to 8 pm ET, Monday-Friday

Visit www.BMSAccessSupport.com

The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding coverage or reimbursement for any service or item.

Register to receive more
information about ONUREG®

Bristol-Myers Squibb Company values your privacy. Bristol-Myers Squibb Company, its affiliates, and its agents will not sell or rent your personal information. By providing your information, you acknowledge that you have read and agree to the Bristol-Myers Squibb Company Privacy Policy.

  • Register to receive updates about ONUREG®

    *Required field

  • Bristol-Myers Squibb Company values your privacy.Bristol-Myers Squibb Company, its affiliates, and its agents will not sell or rent your personal information. By providing your information, you acknowledge that you have read and agree to the Bristol-Myers Squibb Company Privacy Policy.